Robert W. Baird Forecasts Strong Price Appreciation for Agenus (NASDAQ:AGEN) Stock

Agenus (NASDAQ:AGEN - Get Free Report) had its price objective boosted by investment analysts at Robert W. Baird from $4.00 to $6.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has a "neutral" rating on the biotechnology company's stock. Robert W. Baird's price objective would suggest a potential upside of 0.84% from the stock's current price.

AGEN has been the topic of a number of other reports. Wall Street Zen upgraded shares of Agenus from a "strong sell" rating to a "hold" rating in a research note on Thursday, May 22nd. HC Wainwright raised shares of Agenus from a "neutral" rating to a "buy" rating and set a $25.00 price target for the company in a research report on Wednesday. Finally, B. Riley reiterated a "buy" rating on shares of Agenus in a research note on Monday, April 21st. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, Agenus has an average rating of "Hold" and a consensus target price of $14.00.

Agenus Stock Up 15.3%

NASDAQ:AGEN traded up $0.79 on Wednesday, hitting $5.95. The stock had a trading volume of 2,534,211 shares, compared to its average volume of 653,701. The company has a fifty day moving average price of $2.97 and a two-hundred day moving average price of $2.96. The stock has a market cap of $163.13 million, a price-to-earnings ratio of -0.53 and a beta of 1.43. Agenus has a 1-year low of $1.38 and a 1-year high of $18.74.

Agenus (NASDAQ:AGEN - Get Free Report) last posted its earnings results on Monday, May 12th. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.61) by $0.58. The business had revenue of $24.07 million for the quarter, compared to analyst estimates of $26.38 million. As a group, analysts anticipate that Agenus will post -12.55 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. Corton Capital Inc. acquired a new position in Agenus in the fourth quarter valued at approximately $36,000. Apollon Wealth Management LLC boosted its holdings in shares of Agenus by 25.0% in the 1st quarter. Apollon Wealth Management LLC now owns 25,007 shares of the biotechnology company's stock valued at $38,000 after buying an additional 5,000 shares in the last quarter. Virtu Financial LLC acquired a new stake in Agenus during the 4th quarter worth $51,000. Acadian Asset Management LLC purchased a new stake in Agenus in the first quarter valued at $58,000. Finally, Bank of Montreal Can acquired a new position in Agenus in the fourth quarter valued at $69,000. 61.46% of the stock is owned by institutional investors and hedge funds.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.